JAMA Neurol:帕金森症患者早期体重减轻可能预示着病情加重

2016-01-12 崔倩 译 MedSci原创

一项由马萨诸塞州总医院(MGH)领导的调查研究发现帕金森病患者早期体重下降与更快的疾病进展有关。虽然研究结果显示帕金森病患者体重下降是很常见的—这是JAMA Neurology在三月份时发表的一项研究—疾病过程中体重下降可能意味着更严重的一种神经退行性疾病。“我想我们可以看到这种疾病的几种亚型,”MGH神经病学和神经临床研究所,JAMA神经病学论文的通讯作者,医学博士Anne-Marie Will

一项由马萨诸塞州总医院(MGH)领导的调查研究发现帕金森病患者早期体重下降与更快的疾病进展有关。虽然研究结果显示帕金森病患者体重下降是很常见的——这是JAMA Neurology在三月份时发表的一项研究——但疾病过程中体重下降可能意味着更严重的一种神经退行性疾病。

“我想我们可以看到这种疾病的几种亚型,”MGH神经病学和神经临床研究所医学博士,该论文(刊登在JAMA神经病学)的通讯作者Anne-Marie Wills说。“经历过早期体重下降的患者病情似乎更重,这可能是由于神经内分泌系统或胃肠神经系统的参与引起的,而那些体重增加的患者疾病可能没有那么重。”

虽然以前的研究发现,较高的身体质量指数(BMI)与亨廷顿症和肌萎缩侧索硬化症(ALS)患者改善生存有关,但没有发表的研究报告也探讨了疾病进展过程中体重和生存的关系。Wills与来自其他八个美国研究中心的共同作者,收集l从2007年到2013年间的美国国立卫生研究院资助的临床试验数据,调查了早期使用肌酸治疗的情况。该试验招募了1700多例患者,这些患者均在确诊五年之内,在开始使用多巴胺释放药物的90天到两年时被招募,并且发现当肌酸治疗有任何好处时及时停止。

目前的研究所需要数据——包括每年的身高和体重的测量,而且统一帕金森病评定量表(UPDRS)覆盖了试验招募三到五年的结果——1673名研究参与者的数据可用。对于77%的参与者(1282例),在研究期间BMI保持稳定;158名参与者(9%)出现体重减轻,233名参与者(14%)的实际体重增加。这些在研究期间体重减轻的患者,UPDRS评分平均增加较多,这表明症状恶化,说明无论是在运动症状还是对于整体而言,体重减轻都要比那些体重保持稳定的患者情况要糟糕。体重增加的参与者每年UPDRS评分增加幅度最小。三组间生存率无显著的差异,但这可能反映了一个事实,即参加者是在他们的疾病的早期阶段。

作者指出,目前无法确定保持甚至增加体重是否有助于减缓病情发展,但这一假说是Wills在2014年的ALS上的一个介入研究中提出的。Wills是哈佛医学院的神经学助理教授:“由于这仅仅是在帕金森病的研究中第一次观察该关联,我们不推荐目前标准的临床护理的任何更改,”她说,“但在我自己的实践中,我试图阻止患者体重下降,我还会建议医生要细心观察患者的体重变化,甚至在疾病的早期。”

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799546, encodeId=2fc11e9954690, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Mar 30 17:35:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999634, encodeId=c7ee199963412, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 23 12:35:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764977, encodeId=2f971e64977e0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Mon Dec 05 09:35:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407220, encodeId=f291140e22050, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518862, encodeId=905f1518862d9, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799546, encodeId=2fc11e9954690, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Mar 30 17:35:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999634, encodeId=c7ee199963412, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 23 12:35:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764977, encodeId=2f971e64977e0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Mon Dec 05 09:35:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407220, encodeId=f291140e22050, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518862, encodeId=905f1518862d9, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-23 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799546, encodeId=2fc11e9954690, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Mar 30 17:35:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999634, encodeId=c7ee199963412, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 23 12:35:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764977, encodeId=2f971e64977e0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Mon Dec 05 09:35:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407220, encodeId=f291140e22050, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518862, encodeId=905f1518862d9, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799546, encodeId=2fc11e9954690, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Mar 30 17:35:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999634, encodeId=c7ee199963412, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 23 12:35:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764977, encodeId=2f971e64977e0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Mon Dec 05 09:35:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407220, encodeId=f291140e22050, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518862, encodeId=905f1518862d9, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799546, encodeId=2fc11e9954690, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Mar 30 17:35:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999634, encodeId=c7ee199963412, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jan 23 12:35:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764977, encodeId=2f971e64977e0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Mon Dec 05 09:35:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407220, encodeId=f291140e22050, content=<a href='/topic/show?id=dc4b26688c5' target=_blank style='color:#2F92EE;'>#体重减轻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26688, encryptionId=dc4b26688c5, topicName=体重减轻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee42614858, createdName=whlxd, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518862, encodeId=905f1518862d9, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Thu Jan 14 12:35:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-14 howi

相关资讯

芹黄素可用于治疗神经退行性疾病!

研究人员认为,芹黄素(在红辣椒、洋甘菊和许多其他植物和草药中发现)可用于治疗许多神经退行性疾病,包括老年痴呆症、帕金森症和精神分裂症等。

FDA批准帕金森症长效疗法上市

随着老年化社会的进程,医药企业都越来越重视如帕金森症、阿尔兹海默症等神经退行性疾病的研究。然而,限于目前医学界对这类疾病认识水平,这类药物也一直是医药产业界的重灾区。不过,最近艾伯维宣布公司开发的用于治疗晚期帕金森症患者运动波动的药物DUOPA获得FDA的上市批准,这一利好消息无疑对今后生物医药产业界更好地开发这类药物打了一针强心剂。 DUOPA是目前市面上第一种畅销治疗帕金森症患者运动

Neurol Sci.:认知行为与心理动力学疗法用于帕金森症患者抑郁的治疗

众多实践指南推荐认知行为治疗(CBT)和心理动力学疗法可作为治疗帕金森病(PD)患者抑郁症的首选。然而目前尚未有研究分析简易心理治疗(同时包含CBT和心理动力学疗法)在成人帕金森病(PD)患者抑郁症治疗时的效果,于是我们决定开展这样的系统回顾和meta分析。我们收纳了随机对照试验(RCT),这些研究将对照组,其他护理治疗法,或者药物疗法与简易心理治疗作评价以上方案的治疗效果。 通过严格的质量评估,

帕金森症患者的福音!FDA批准艾伯维帕金森症长效疗法上市

随着老年化社会的进程,医药企业都越来越重视如帕金森症、阿尔兹海默症等神经退行性疾病的研究。然而,限于目前医学界对这类疾病认识水平,这类药物也一直是医药产业界的重灾区。不过,最近艾伯维宣布公司开发的用于治疗晚期帕金森症患者运动波动的药物DUOPA获得FDA的上市批准,这一利好消息无疑对今后生物医药产业界更好地开发这类药物打了一针强心剂。 DUOPA是目前市面上第一种畅销治疗帕金森症患者运动波动

谷歌研制的“帕金森症”智能勺子正式发售

11月26日消息,据国外媒体报道,谷歌早前为“帕金森症”患者特别研制的防抖动智能勺子(Liftware Spoon)如今已正式在Lift官方网站上销售。该产品零售单价为295美元,号称能有效的减少抖动影响约76%。 Liftware Spoon的生产商为Lift Lab,该公司在今年早些时候被谷歌收购。如今,Lift Lab创始人安奴潘•帕塔克(Anupam Pathak)已在为谷歌X实验

植入这个离子泵,再也不怕痛

研究人员研发出了一种有机离子晶体管,能够有效阻断疼痛信号达到小鼠的大脑。        瑞典林雪平大学研发出了一种最新的医疗设备,能够在合适的时机发送人体独有的天然疼痛缓解信号。有朝一日能够用于解救慢性疼痛患者。林雪平大学研发的这台用有机电子器件制成的小小的“离子泵”植入病人的体内,在疼痛信号传递到大脑之前,在脊椎进行拦截。这个小小的离子泵的作用原